{"brief_title": "Study to Assess the Efficacy and Safety of Rituximab in Patients With Rheumatoid Arthritis", "brief_summary": "This study will assess the efficacy and safety of different treatment regimens of rituximab (MabThera\u00ae/Rituxan\u00ae), corticosteroids, and placebo, combined with methotrexate (MTX), in patients with active rheumatoid arthritis (RA).", "condition": "Rheumatoid Arthritis", "intervention_type": "Drug", "intervention_name": "placebo", "description": "Intravenous repeating dose", "arm_group_label": "9", "criteria": "Eligibility criteria include, but are not limited to the following: - Are between the ages of 18 and 80 years. - Have been diagnosed with rheumatoid arthritis for at least 6 months. - Have failed treatment (lack of efficacy) with at least 1 but no more than 5 disease-modifying anti-rheumatic drugs or biologics (other than methotrexate).", "gender": "All", "minimum_age": "18 Years", "maximum_age": "80 Years", "healthy_volunteers": "No", "id": "NCT00074438.xml"}